Preventive and/or ameliorative agent for diseases, stamina enhancement agent, anti-fatigue agent, and pharmaceutical and food and drink using them

Abstract

A purple non-sulfur bacteria useful in preventing and/or ameliorating at least one disease selected from the group consisting of inflammatory diseases, allergic diseases, and autoimmune diseases and having high safety is provided. A preventive and/or ameliorative agent is for at least one disease selected from the group consisting of inflammatory diseases, allergic diseases, and autoimmune diseases and includes at least one of a purple non-sulfur bacteria and a culture material obtained by culturing the purple non-sulfur bacteria. The purple non-sulfur bacteria includes Rhodobacter azotoformans.

1 . A preventive and/or ameliorative agent for at least one disease selected from the group consisting of inflammatory diseases, allergic diseases, and autoimmune diseases, the preventive and/or ameliorative agent comprising:
 at least one of a purple non-sulfur bacteria and a culture material obtained by culturing the purple non-sulfur bacteria, wherein   the purple non-sulfur bacteria comprises  Rhodobacter azotoformans.      
     
     
         2 . The preventive and/or ameliorative agent according to  claim 1 , wherein
 the  Rhodobacter azotoformans  comprises the following bacteriological characteristics (1) to (30):   (1) cell morphology: a rod shape or an oval shape;   (2) polymorphism: negative;   (3) cell size: 0.8 μm×1.0 μm;   (4) the presence or absence of motility: positive;   (5) the presence or absence of spore: negative;   (6) luster in nutrient agar culture: positive;   (7) pigment production in nutrient agar culture: positive;   (8) the presence or absence of surface growth in nutrient broth culture: negative;   (9) the presence or absence of medium turbidity in nutrient broth culture: positive;   (10) liquefaction of gelatin in gelatin stab culture: negative;   (11) coagulation in litmus-milk culture: negative;   (12) liquefaction in litmus-milk culture: negative;   (13) Gram staining: negative;   (14) reduction of nitrate salt: negative;   (15) denitrification: negative or positive;   (16) MR test: negative;   (17) production of indole: negative;   (18) generation of hydrogen sulfide: negative;   (19) hydrolysis of starch: negative;   (20) utilization of citric acid (Christensen): negative;   (21) utilization of inorganic nitrogen source (ammonium salt): positive;   (22) generation of catalase: positive;   (23) generation of oxidase: positive;   (24) anaerobic growth: positive;   (25) O-F test (oxidation/fermentation): negative/negative;   (26) β-galactosidase activity: negative;   (27) arginine dihydrolase activity: negative;   (28) lysine decarboxylase activity: negative;   (29) tryptophan deaminase activity: negative; and   (30) gelatinase activity: negative.   
     
     
         3 . The preventive and/or ameliorative agent according to  claim 1 , wherein
 a base sequence of 16S-rRNA in the  Rhodobacter azotoformans  is a base sequence represented by SEQ ID NO: 1.   
     
     
         4 . The preventive and/or ameliorative agent according to  claim 1 , wherein
 the  Rhodobacter azotoformans  is  Rhodobacter azotoformans  BP0899 strain (Accession No. NITE BP-644).   
     
     
         5 . A stamina enhancement agent comprising:
 at least one of a purple non-sulfur bacteria and a culture material obtained by culturing the purple non-sulfur bacteria; and   the purple non-sulfur bacteria comprises  Rhodobacter azotoformans.      
     
     
         6 . The stamina enhancement agent according to  claim 5 , wherein
 the  Rhodobacter azotoformans  comprises the following bacteriological characteristics (1) to (30):   (1) cell morphology: a rod shape or an oval shape;   (2) polymorphism: negative;   (3) cell size: 0.8 μm×1.0 μm;   (4) the presence or absence of motility: positive;   (5) the presence or absence of spore: negative;   (6) luster in nutrient agar culture: positive;   (7) pigment production in nutrient agar culture: positive;   (8) the presence or absence of surface growth in nutrient broth culture: negative;   (9) the presence or absence of medium turbidity in nutrient broth culture: positive;   (10) liquefaction of gelatin in gelatin stab culture: negative;   (11) coagulation in litmus-milk culture: negative;   (12) liquefaction in litmus-milk culture: negative;   (13) Gram staining: negative;   (14) reduction of nitrate salt: negative;   (15) denitrification: negative or positive;   (16) MR test: negative;   (17) production of indole: negative;   (18) generation of hydrogen sulfide: negative;   (19) hydrolysis of starch: negative;   (20) utilization of citric acid (Christensen): negative;   (21) utilization of inorganic nitrogen source (ammonium salt): positive;   (22) generation of catalase: positive;   (23) generation of oxidase: positive;   (24) anaerobic growth: positive;   (25) O-F test (oxidation/fermentation): negative/negative;   (26) β-galactosidase activity: negative;   (27) arginine dihydrolase activity: negative;   (28) lysine decarboxylase activity: negative;   (29) tryptophan deaminase activity: negative; and   (30) gelatinase activity: negative.   
     
     
         7 . The stamina enhancement agent according to  claim 5 , wherein
 a base sequence of 16S-rRNA in  Rhodobacter azotoformans  is a base sequence represented by SEQ ID NO: 1.   
     
     
         8 . The stamina enhancement agent according to  claim 5 , wherein
 the  Rhodobacter azotoformans  is  Rhodobacter azotoformans  BP0899 strain (Accession No. NITE BP-644).   
     
     
         9 . An anti-fatigue agent comprising:
 at least one of a purple non-sulfur bacteria and a culture material obtained by culturing the purple non-sulfur bacteria, wherein   the purple non-sulfur bacteria comprises  Rhodobacter azotoformans.      
     
     
         10 . The anti-fatigue agent according to  claim 9 , wherein
 the  Rhodobacter azotoformans  comprises the following bacteriological characteristics (1) to (30):   (1) cell morphology: a rod shape or an oval shape;   (2) polymorphism: negative;   (3) cell size: 0.8 μm×1.0 μm;   (4) the presence or absence of motility: positive;   (5) the presence or absence of spore: negative;   (6) luster in nutrient agar culture: positive;   (7) pigment production in nutrient agar culture: positive;   (8) the presence or absence of surface growth in nutrient broth culture: negative;   (9) the presence or absence of medium turbidity in nutrient broth culture: positive;   (10) liquefaction of gelatin in gelatin stab culture: negative;   (11) coagulation in litmus-milk culture: negative;   (12) liquefaction in litmus-milk culture: negative;   (13) Gram staining: negative;   (14) reduction of nitrate salt: negative;   (15) denitrification: negative or positive;   (16) MR test: negative;   (17) production of indole: negative;   (18) generation of hydrogen sulfide: negative;   (19) hydrolysis of starch: negative;   (20) utilization of citric acid (Christensen): negative;   (21) utilization of inorganic nitrogen source (ammonium salt): positive;   (22) generation of catalase: positive;   (23) generation of oxidase: positive;   (24) anaerobic growth: positive;   (25) O-F test (oxidation/fermentation): negative/negative;   (26) β-galactosidase activity: negative;   (27) arginine dihydrolase activity: negative;   (28) lysine decarboxylase activity: negative;   (29) tryptophan deaminase activity: negative; and   (30) gelatinase activity: negative.   
     
     
         11 . The anti-fatigue agent according to  claim 9 , wherein
 a base sequence of 16S-rRNA in the  Rhodobacter azotoformans  is a base sequence represented by SEQ ID NO: 1.   
     
     
         12 . The anti-fatigue agent according to  claim 9 , wherein
 the  Rhodobacter azotoformans  is  Rhodobacter azotoformans  BP0899 strain (Accession No. NITE BP-644).   
     
     
         13 . A pharmaceutical for preventing and/or ameliorating at least one disease selected from the group consisting of inflammatory diseases, allergic diseases, and autoimmune diseases, the pharmaceutical comprising:
 the preventive and/or ameliorative agent according to  claim 1 .   
     
     
         14 . A pharmaceutical comprising:
 at least one of the stamina enhancement agent according to  claim 5  and;   an anti-fatigue agent comprising:   at least one of a purple non-sulfur bacteria and a culture material obtained by culturing the purple non-sulfur bacteria, wherein   the purple non-sulfur bacteria comprises  Rhodobacter azotoformans.      
     
     
         15 . Food and drink, for preventing and/or ameliorating at least one disease selected from the group consisting of inflammatory diseases, allergic diseases, and autoimmune diseases, the food and drink comprising:
 the preventive and/or ameliorative agent according to  claim 1 .   
     
     
         16 . Food and drink, comprising:
 at least one of the stamina enhancement agent according to  claim 5  and   an anti-fatigue agent:   at least one of a purple non-sulfur bacteria and a culture material obtained by culturing the purple non-sulfur bacteria, wherein   the purple non-sulfur bacteria comprises  Rhodobacter azotoformans.      
     
     
         17 . A purple non-sulfur bacteria being  Rhodobacter azotoformans  BP0899 strain (Accession No. NITE BP-644). 
     
     
         18 . A method for preventing and/or ameliorating at least one disease selected from the group consisting of inflammatory diseases, allergic diseases, and autoimmune diseases, the method comprising the step of:
 administering a preventive and/or ameliorative agent comprising at least one of a purple non-sulfur bacteria and a culture material obtained by culturing the purple non-sulfur bacteria, wherein   the purple non-sulfur bacteria comprises  Rhodobacter azotoformans.      
     
     
         19 . A stamina enhancement method, comprising the step of:
 administering a stamina enhancement agent comprising at least one of a purple non-sulfur bacteria and a culture material obtained by culturing the purple non-sulfur bacteria, wherein   the purple non-sulfur bacteria comprises  Rhodobacter azotoformans.      
     
     
         20 . An anti-fatigue method comprising the step of:
 administering an anti-fatigue agent comprising at least one of a purple non-sulfur bacteria and a culture material obtained by culturing the purple non-sulfur bacteria, wherein   the purple non-sulfur bacteria comprises  Rhodobacter azotoformans.      
     
     
         21 - 22 . (canceled)